Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
Stites E, Shaw A. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. CPT Pharmacometrics & Systems Pharmacology 2018, 7: 342-351. PMID: 29484842, PMCID: PMC5980551, DOI: 10.1002/psp4.12291.Peer-Reviewed Original ResearchConceptsRegulates Ras activitySystems biology approachBiology approachRas activationProtein turnoverKRAS-G12C covalent inhibitorsKRAS G12C inhibitorsSystems pharmacology analysisRasKRAS mutantDrug developmentG12C inhibitorsCovalent inhibitorsInhibitorsKRASMutantsPharmacological analysisMutationsKRAS G12CTumour-immune dynamics with an immune checkpoint inhibitor
Nikolopoulou E, Johnson L, Harris D, Nagy J, Stites E, Kuang Y. Tumour-immune dynamics with an immune checkpoint inhibitor. Letters In Biomathematics 2018, 5: s137-s159. DOI: 10.1080/23737867.2018.1440978.Peer-Reviewed Original ResearchProteins programmed death-1Anti-PD-1Immune checkpoint inhibitorsTumor-immune dynamicsCheckpoint inhibitorsAnti-PD-1 drugsLigand PD-L1Eradicate tumor cellsTumor immune responseFunctional immune systemAntitumour responseDeath-1PD-L1Tumor-freeControl tumorsTumor equilibriumTumor cellsClinical trialsContinuous treatmentImmune systemTreatmentTumor-immune modelInhibitorsTumorTherapy